Evaluating the Therapeutic Effect of Sofosbuvir in Outpatients with COVID-19: A Randomized Clinical Trial Study
2024

Evaluating the Effect of Sofosbuvir in COVID-19 Outpatients

Sample size: 360 publication Evidence: low

Author Information

Author(s): Haddadzadeh Shoushtari Maryam, Raji Hanieh, Borsi Seyed Hamid, Tavakol Heshmatollah, Cheraghian Bahman, Moeinpour Mahtab

Primary Institution: Ahvaz Jundishapur University of Medical Sciences

Hypothesis

Can sofosbuvir effectively reduce symptoms and hospitalization in outpatients with mild COVID-19?

Conclusion

Sofosbuvir alone cannot significantly improve the treatment outcomes for outpatients with mild COVID-19.

Supporting Evidence

  • The study involved 360 patients with mild COVID-19.
  • Patients were randomly assigned to receive either sofosbuvir or a placebo.
  • Results showed no significant differences in symptom duration or hospitalization rates between the two groups.

Takeaway

This study looked at whether a medicine called sofosbuvir helps people with mild COVID-19 feel better faster, but it didn't really make a difference.

Methodology

This was a randomized clinical trial with 360 patients divided into intervention and control groups, assessing symptoms and hospitalization after treatment with sofosbuvir or placebo.

Potential Biases

The study was triple-blind to minimize bias, but potential biases in patient selection and reporting could still exist.

Limitations

The study only included outpatients with mild COVID-19, which may limit the generalizability of the findings to more severe cases.

Participant Demographics

Participants were outpatients with mild COVID-19, with a mix of genders and ages ranging from 18 to 70 years.

Digital Object Identifier (DOI)

10.31661/gmj.v12i.3035

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication